SCHEMBL29800922

SCHEMBL29800922

CN(C)c1cccnc1S(=O)(=O)Nc1cccc2c1NCCC2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EDNRA P25101 3/20 0.37
▸ SLC40A1 Q9NP59 6/20 0.37
▸ SRC P12931 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.35
▸ NSD2 O96028 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ ALDH1A1 P00352 4/20 0.35
▸ HTR6 P50406 2/20 0.34
▸ TDP1 Q9NUW8 5/20 0.33
▸ LMNA P02545 3/20 0.33
▸ HTT P42858 3/20 0.33
▸ AGTR1 P30556 2/20 0.33
▸ OPRK1 P41145 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ MITF O75030 1/20 0.33
▸ S1PR4 O95977 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ S1PR1 P21453 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27214232 1.00 EDNRA (0.37) EDNRASLC40A1SRCKDM4ENSD2
SCHEMBL26964361 0.85 ALDH1A1 (0.42) SLC40A1SRCKDM4EALDH1A1TDP1
SCHEMBL29800812 0.85 ALDH1A1 (0.42) SLC40A1SRCKDM4EALDH1A1TDP1
SCHEMBL29800962 0.85 ALDH1A1 (0.42) SLC40A1SRCKDM4EALDH1A1TDP1
SCHEMBL30553402 0.83 SLC40A1 (0.43) SLC40A1SRCKDM4EALDH1A1TDP1
SCHEMBL26964376 0.83 SLC40A1 (0.43) SLC40A1SRCKDM4EALDH1A1TDP1
SCHEMBL29800372 0.76 EDNRA (0.34) EDNRASLC40A1KDM4ENSD2TSHR
SCHEMBL26964541 0.76 EDNRA (0.34) EDNRASLC40A1KDM4ENSD2TSHR
SCHEMBL30925521 0.74 GLO1 (0.59) SLC40A1ALDH1A1TDP1LMNAHTT
SCHEMBL27214186 0.74 GLO1 (0.59) SLC40A1ALDH1A1TDP1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed
EP-4291555-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES Celgene Corporation (US) 2023-12-20 — — EP disclosed
CN-116806218-A Sulfonamide and its use for the treatment of parasitic helminth infections and diseases 新基公司 2023-09-26 — — CN disclosed
WO-2022173727-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES CELGENE CORPORATION (US) 2022-08-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 EDNRA 1570/4885SLC40A1 3357/4885SRC 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback